CARLSBAD, Calif. - (Marketwired – December 16, 2014) - International Stem Cell Corporation (OTCQB:ISCO), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced that ISCO has been included in the 2014 Technology Fast 500™ ranking of the fastest growing North American companies by Deloitte, one of the world’s largest and well respected organizations providing audit, tax, consulting, and financial advisory services in more than 150 countries.
"Being highlighted by Deloitte as one of America’s fastest growing companies both enhances our reputation and formally acknowledges our achievements over the last few years,” said Andrey Semechkin PhD ISCO's CEO and Co-Chairman. “With biotechnology companies making up about 10% of the list, this makes ISCO one of the top fifty fastest growing biotechnology companies in America and also the only stem cell company represented.” Dr. Semechkin concluded.
ISCO’s quoted growth rate of 448% over the selected financial period places the company at # 215 in the Fast 500 list, which also includes the fastest growing technology, media, telecommunications and clean tech companies. Not surprisingly, over half of the companies on Deloitte’s Fast 500 list (64%) are either software or internet companies. About 10% of the Fast 500 are biotechnology companies and of those 47 biotechnology businesses, ISCO is ranked 21st. International Stem Cell Corporation is also the only regenerative medicine company to make the Fast 500 list. The full list can be found here http://www2.deloitte.com/content/dam/Deloitte/us/Documents/us-tmt-fast500-2014-ranking-list.pdf
Deloitte’s Technology Fast 500 provides a ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies — both public and private — in North America (U.S. and Canada) with award winners for 2014 being selected based on percentage fiscal year revenue growth during the period from 2009 to 2013. In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year (2009) operating revenues of at least $50,000 USD or CD, and current-year (2013) operating revenues of at least $5 million USD or CD. Additionally, companies must be in business for a minimum of five years, and be headquartered within North America.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com or follow us on Twitter @intlstemcell.
To receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
International Stem Cell Corporation
Simon Craw Ph.D.
Executive Vice President
Tony Russo, Ph.D.
Phone: (212) 845-4251
Martina Schwarzkopf, Ph.D.
Phone: (212) 845-4292